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Therapies to limit or reverse fibrosis have proven
unsuccessful, highlighting the need for a greater un-
derstanding of basic mechanisms that drive fibrosis
and, in particular, the link between fibrosis and in-
flammation. It has been shown that pro-fibrotic trans-
forming growth factor 1 (TGF-1)–driven epithelial-
to-mesenchymal transition (EMT) can be accentuated
by tumor necrosis factor  (TNF-). TGF-–activated
kinase 1 (TAK1) is activated by both TGF-1 and
TNF-, activating both nuclear factor kappa-light-
chain-enhancer of activated B cells and mitogen-acti-
vated protein kinase signaling pathways. In this
study, we evaluated the potential for TAK1 to modu-
late the synergistic effect between TGF-1 and TNF-
in driving EMT. Co-stimulation with TGF-1 and TNF-
induced an accentuated and extended phosphorylation
of TAK1 compared to either alone. TAK1 signaled
downstream via nuclear factor kappa-light-chain-en-
hancer of activated B cells, and Jun N-terminal ki-
nase-2, but independent of Jun N-terminal kinase-1,
extracellular signal-regulated kinase-1/2, or p38 mito-
gen-activated protein kinase signaling to drive EMT in
bronchial epithelial cells. Blocking either TAK1 or Jun
N-terminal kinase-2 inhibited EMT. TAK1 phosphory-
lation was increased in the airway epithelium of pa-
tients with fibrotic airway disease. These data identify
factors leading to and affected by accentuated and
extended TAK1 phosphorylations potential novel
therapeutic targets in inflammation-driven fibroticdiseases. (Am J Pathol 2012, 180:2293–2308; http://dx.doi.
org/10.1016/j.ajpath.2012.02.022)
Fibrosis can affect multiple organs, including the lung, kid-
ney, and liver, despite obvious etiological differences; it is
hypothesized that the mechanisms leading to fibrosis may
share a common cellular pathway. Our group has previ-
ously demonstrated in vivo and in vitro evidence that epithe-
lial cells can undergo transforming growth factor-1 (TGF-
1)-driven epithelial to mesenchymal transition (EMT) and
that this phenomenon is involved in the expansion of the
myofibroblast population during the development of obliter-
ative bronchiolitis (OB),1,2 a progressive disease of the
small and medium airways resulting in airway obstruction
and respiratory failure in the transplant airway.3
EMT is a process whereby epithelial cells lose their
epithelial phenotype and functionality, including cell-to-
cell adherence and polarity, whereas gaining character-
istics typically associated with mesenchymal cells, such
as an invasive phenotype and the ability to secrete ex-
tracellular matrix components.4 This transition is associ-
ated with a decrease in E-cadherin, cytokeratin, and zona
occludens-1 expression concurrent with an increase in
vimentin, fibronectin, and N-cadherin expression. Fur-
thermore, a change in the secretory profile of the cells is
observed, including an increased secretion of matrix
metalloproteinases (MMP) and collagen.
TGF-1 is a pleiotropic molecule involved in numerous
cell functions, such as modulation of the cell cycle and
apoptosis, and has been shown to be elevated in the
airways of patients with OB.1 In addition, TGF-1 contin-
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sis in multiple organs.5–7 On binding to its receptor,
TGF-1 initiates the phosphorylation of a SMAD protein,
which can then form a transcriptionally active het-
erodimer or trimer with other SMAD family proteins,8,9 a
process which has been shown to be important in driving
fibrosis and EMT.10,11
However, TGF-1 can also signal via activation of the
mitogen-activated protein kinase cascade.12,13 The mito-
gen-activated protein kinase cascade consists of several
distinct signaling pathways, including extracellular signal-
regulated kinase (ERK)-1/2, c-Jun N-terminal kinase (JNK)-
1/2, and p38.12,13 The mitogen-activated protein kinase-3
TGF- activated kinase 1 (TAK1) is thought to play a key
role in the initiation of noncanonical TGF- signaling.
The role of inflammation in the development of fibrosis
remains poorly understood. Recently it has been demon-
strated by our group and others that the inflammatory
cytokine tumor necrosis factor  (TNF-) can accentuate
TGF-1–driven EMT.2,14,15 TNF- signals through two
distinct transmembrane receptors, tumor necrosis factor
receptor 1 (TNFR1) and tumor necrosis factor receptor 2
(TNFR2).16 TNFR1 is ubiquitously expressed and can
respond to both membrane-bound and soluble (TNFsol)
forms of TNF-, whereas TNFR2 is highly regulated in its
expression, mainly on immune cells, and responds effi-
ciently, only to membrane-bound TNF-.17
The canonical signaling pathway activated by TNF-
has been extensively investigated in response to TNFR1
activation which induces a signaling cascade via nuclear
factor kappa-light-chain-enhancer of activated B cells
(NF-B). TNFR1 recruits TNF-receptor–associated factor
2 (TRAF2) along with E3 ubiquitin ligases forming a com-
plex that activates TAK1 via polyubiquitination. Activated
TAK1 recruits the IB kinase (IKK) complex composed of
three subunits, the regulatory IKK and the catalytic IKK
and IKK, which are responsible for the degradation of
I-B and subsequent activation of NF-B signaling.18–20
In this study, we comprehensively investigate the role
of TAK1 in TGF-1–driven, TNF-–accentuated EMT, and
investigated the downstream signaling mechanisms in-
volved in this synergy. We, furthermore, investigated
TAK1 phosphorylation and localization in epithelial cells
in lung tissue from patients with fibrotic airway disease
(OB) and normal controls.
Materials and Methods
Antibodies
TNFR1 (HM2020; Hycult, Uden, The Netherlands) and
TNFR2 (HM2007; Hycult)21 primary antibodies were used
to detect receptor expression by flow cytometry. E-cad-
herin (610181; Becton, Dickinson and Company, Oxford,
UK), fibronectin (F3648; Sigma-Aldrich, Poole, UK), cyto-
keratin-19 (sc-6278; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), vimentin (sc-6260; Santa Cruz Biotech-
nology) and -actin (a2228; Sigma-Aldrich) primary anti-
bodies were used throughout this study for the detection
of changes in EMT marker expression. TAK1 (4505; CellSignaling, Danvers, MA), phospho-TAK1 (4536; Cell Sig-
naling), SMAD3 (ab29379; Abcam, Cambridge, UK),
phospho-SMAD3 (ab52903; Abcam), IKK (2370; Cell
Signaling), phospho-IKK/ (2681; Cell Signaling), JNK-
1/2 (9252; Cell Signaling), phospho-JNK-1/2 (4668; Cell
Signaling), p38 (sc-7149; Santa Cruz Biotechnology),
phospho-p38 (ab4822; Abcam), ERK-1/2 (4695; Cell Sig-
naling), phospho-ERK-1/2 (4370; Cell Signaling), phos-
pho-I-B (9246; Cell Signaling), I-B (sc-1643; Santa
Cruz Biotechnology), phospho-c-Jun (2361; Cell Signal-
ing), c-Jun (9165; Cell Signaling), TAB1 (3226; Cell Sig-
naling), TAB2 (3745; Cell Signaling), and TAB3
(ab85655; Abcam) primary antibodies were used
throughout this study for the detection of changes in
protein phosphorylation, localization, and association.
Anti-rabbit IgG (ab37415; Abcam) was used to pre-clear
cell lysate before TAK1 or JNK-1/2 immunoprecipitation.
RAN (4462; Cell Signaling) primary antibody was used as
a control for protein localization Western blots.
Cell Isolation and Culture
Primary bronchial epithelial cells (PBECs) were isolated
from stable lung transplant patients via airway brushings,
as previously described.22 PBECs were cultured at
3500 cells/cm2 in small airway growth media (CC-3118;
Lonza, Basel, Switzerland) on either collagen (5005-B;
Nutacon, Leimuiden, The Netherlands) (0.5% collagens I
and III) coated glass cover slips or collagen-coated tis-
sue culture flasks. This study was performed in accor-
dance with approval from the Newcastle and North Tyne-
side Local Regional Ethics Committee and informed
written consent from all study patients.
Cell Treatment
PBECs were cultured with or without TGF-1 (10 ng/mL)
(100–21; Peprotech, London, UK) or TNF- (20 ng/mL)
(PHC3015; Invitrogen, Paisley, UK) for 72 hours for the
assessment of EMT marker expression. The times used for
phosphorylation assays were protein dependent and are
described for each result. Cells were treated with TNF-,
wild-type TNF- (TNFcys), TNFR1-specific mutant (Cys-
TNF32W/86T) TNF (TNFcysR1), or TNFR2-specific mutant
(Cys-TNF143N/145R) TNF (TNFcysR2) that oligomerize due
to cystine residues at the N-terminal, allowing the molecules
to mimic transmembrane surface expressed TNF- (all 20
ng/mL).23,24 SMAD3 (SMADi–specific inhibitor of SMAD3;
10 mol/L) (566405; Calbiochem, Nottingham, UK), p38
(p38i–SB 203580; 10 mol/L) (559389; Calbiochem), ERK-
1/2 (ERKi)(FR180204; 5 mol/L) (328007; Calbiochem),
JNK-1/2 (JNKi)(SAPK Inhibitor II; 5 mol/L) (420119; Calbi-
ochem), IKK (IKKi)(IKK-2 Inhibitor IV; 5 mol/L) (401481;
Calbiochem), or TAK1 chemical inhibitors (TAKi)[(5Z)-7-
Oxozeaenol, Curvularia sp; 1 mol/L] (499610; Calbi-
ochem); were added to cells 1 hour before stimulation with
TGF-1 or TNF-, as previously described. Dose response
curves for each inhibitor looking at effect on EMT and cell
viability were used to select appropriate inhibitor concen-
trations. SMAD3 (SMADsi; 5 nmol/L) (SI00082481; Qiagen,
Crawley, UK) (5=-ATCAAGGGATTTCCTATGGAA-3=), IKK
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GAGAAGTACAGCGAGCAA-3=), TAK1 (TAKsi; 3 nmol/L)
(SI02758763;Qiagen) (5=-AAGATGGTATATACCAAGTTA-3=),
JNK-1 (JNK-1si; 5 nmol/L) (SI02757209; Qiagen) (5=-GTG-
GAAAGAATTGATATATAA-3=), or JNK-2 siRNA (JNK-2si; 10
nmol/L) (SI00300797; Qiagen) (5=-GCCGUCCUUUUCA-
GAACCAT-3=) si-RNAs; were delivered via lipid transfection
(301705) 24 hours before stimulation with TGF-1 or TNF-. A
sequence scrambled negative control was used in all experi-
ments (3 nmol/L) (SI03650318; Qiagen).
Flow Cytometry
Following treatment, cells were harvested, re-suspended
in phosphate buffered albumin (PBA) [0.25% (w/v) bo-
vine serum albumin, 0.02% (w/v) NaN3 in PBS] containing
TNFR1-specific (5 g/mL) and TNFR2-specific (2.5 g/
mL) antibodies and incubated on ice for 1 hour. Cells
were washed with PBA and incubated with PBA contain-
ing fluorescein isothiocyanate-conjugated secondary an-
tibody for 1 hour on ice. Cells were washed with PBA,
samples were supplemented with 1 g/mL propidium
iodide and analyzed on a BD FACSCanto II flow cytom-
eter (Becton Dickinson Company).
Cellular Fractioning
Nuclear and non-nuclear fractions from PBECs were iso-
lated using the NE-PERNuclear andCytoplasmic Extraction
Kit (78833; Pierce, Rockford, IL), according to the manufac-
turer’s instructions.
SDS-PAGE and Western Blot
Protein concentration was determined using the BCA
Protein Assay kit (23225; Pierce), according to the
manufacturer’s instructions. Total cell lysates (20 to 50
g of protein) were separated on 4% to 12% Bis-Tris
gradient gels (NP0321; Invitrogen) and wet transferred
onto HyBond-P polyvinylidene difluoride membranes
(RPN203N; Amersham, Little Chalfont, UK). Membranes
were blocked [5% (w/v) BSA in TBS-Tween20 (0.5% w/v)]
before incubation with primary antibodies and subse-
quent detection with appropriate horseradish peroxidase
conjugated secondary antibodies (ab6728 and ab16284;
Abcam). Complexes were visualized using SuperSignal
West Pico Chemiluminescent Substrate (34077; Pierce).
Images were acquired using a Syngene G:Box Chemi
(Syngene, Cambridge, UK). Band density was analyzed
using ImageJ.25 Results were normalized to -actin for
EMT markers, and total unphosphorylated protein for
phosphorylation studies.
Gelatin Zymography
Culture medium was separated under nonreducing con-
ditions on an 8% SDS-PAGE gel containing 1% gelatin.
Gels were incubated with 2.5% Triton X-100 for 30 min-
utes and then overnight in substrate buffer (50 mmol/L
Tris-HCl, 200 mmol/L NaCl, and 5 mmol/L CaCl2). Bandswere visualized by staining with Coomassie stain (40%
methanol, 10% acetic acid, and 0.05% Coomassie Bril-
liant Blue R250).
Immunoprecipitation
Starting protein concentration was assayed via bicin-
choninic acid protein assay. Immunoprecipitation of key
signaling proteins was performed using the Catch and
Release kit (17–500; Millipore, Watford, UK), according to
the manufacturer’s instructions with incubation and wash-
ing steps optimized for each antibody. Beads were pre-
cleared with pan-IgG antibody and efficacy and speci-
ficity of isolation determined via SDS-PAGE and Western
blot.
Indirect ELISA
Immunoprecipitates were coated onto 96-well enzyme-
linked immunosorbent assay (ELISA) plates overnight.
Phospho targeting primary antibodies were incubated
overnight before detection with appropriate horserad-
ish peroxidase-conjugated secondary antibodies with te-
tramethylbenzidine peroxide (DY999; R&D Systems,
Abingdon, UK) as the substrate. Selected samples were
analyzed by Western blot to demonstrate selectivity com-
pared to IgG controls.
Sircol Collagen Assay
Secreted collagen (collagens I-IV) was detected in cul-
ture medium using the Sircol Collagen Assay (S1000;
Biocolor, Carrickfergus, UK), according to the manufac-
turer’s instructions.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde and incubated
with primary antibodies overnight before detection with
appropriate fluorochrome conjugate secondary antibod-
ies (fluorescein-isothiocyanate F2012 and tetramethyl-
rhodamine-5-isothiocyanate T6778; Sigma-Aldrich) with
DAPI (H-1200; Vector Labs, Peterborough, UK) used as a
nuclear counterstain. Images were acquired using a
Leica TCS-SP-2UV laser scanning confocal microscope
(Leica, Mannheim, Germany) at 63 magnification, with
consistent acquisition settings used throughout. Intensity
of expression of nuclear expression was analyzed by
isolating nuclei in the blue channel, then recording the
mean pixel intensity in the red channel using Adobe
Photoshop Creative Suite 5 (Adobe Systems Incorpo-
rated, San Jose, CA). Analysis was performed on 20
randomly selected cells from multiple fields.
Immunohistochemistry
Formalin fixed tissue sections from patients with OB and
unused donor lung were de-waxed in Xylenes and rehy-
drated in sequentially decreasing concentrations of eth-
anol. Slides were boiled in 0.1 M EDTA (pH 8.0) for 10
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was then performed as previously described.
Statistical Analysis
Differences in EMT marker expression (normalized to
-actin as a loading control), phosphorylation of key sig-
naling proteins (normalized to the unphosphorylated pro-
tein as a loading control), and collagen secretion were
assessed using a Mann-Whitney U-test. Data are ex-
pressed as mean  SEM. Differences with P values of
0.05 were considered statistically significant.
Results
TNF- Accentuates EMT via TNFR1
TNF-, an inflammatory cytokine capable of accentuating
but not driving EMT, signals via two distinct transmem-
brane receptors (TNFR1 and TNFR2), which play inde-
pendent roles in cellular responses.16,26 Untreated
PBECs express TNFR1 on their cell surface, but express
little to no TNFR2 (Figure 1A). Stimulation with TGF-1
10 ng/mL had no effect on basal TNFR1 or TNFR2
expression on the cell surface in PBECs (data not
shown). To investigate the relative contribution of TNFR1
and TNFR2 ligation on the accentuation of TGF-1–
driven EMT, we used two distinct isoforms of TNF-; the
26 kDa membrane expressed form (TNFcys) and the 17
kDa soluble form (TNFsol). TNFcys can signal via both
TNFR1 and TNFR2, however, TNFsol signals preferentially
via TNFR1.17 Co-stimulation of PBECs with both TGF-1
and TNFsol, or TNFcys strongly accentuates TGF-1–
driven EMT compared to TGF-1 alone, suggesting sig-
naling is occurring via TNFR1. To confirm this, PBECs
were co-treated with TGF-1 and TNFR1 (TNFcysR1), and
TNFR2 (TNFcysR2)-specific mutant TNFcys and EMT as-
sessed. Only TNFcysR1 was able to accentuate TGF-1–
driven EMT confirming the accentuation of TGF-1–driven
EMT occurs via TNFR1 through both TNFsol and TNFcys.
None of the TNF isoforms alone had an effect on EMT
protein marker expression alone, but TNFsol, TNFcys, and
TNFcysR1 alone induced the secretion of pro-MMP-9 (Figure
1, B and C).
Identifying Key Downstream Signaling
Mediators
To identify the key signaling events involved in the syn-
ergistic action of TNF- on TGF-1–driven EMT, the
phosphorylation of key signaling molecules in response
to with TGF-1 or TNF- was investigated. Indirect ELISA
for SMAD3, IKK, TAK1, and JNK-1/2 phosphorylation
were performed on immunoprecipitates isolated from
PBECs whole cell lysates using relevant total antibodies.
TGF-1 induced significant SMAD3 phosphorylation from
30 minutes, which lasted beyond 60 minutes. Stimulation
with TNF- did not induce significant phosphorylation of
SMAD3 at any time point. Co-stimulation of PBECs with
TGF-1 and TNF- induced significant phosphorylationof SMAD3 in a similar fashion to that of TGF-1 alone,
although in both instances phosphorylation was nonsig-
nificantly lower (Figure 2A). TGF-1 did not induce sig-
nificant IKK phosphorylation at any time point, whereas
TNF- induced significant phosphorylation of IKK from 1
minute, peaking at 10 minutes and lasting for 30 minutes.
Co-stimulation with TGF-1 and TNF- induced signifi-
cant phosphorylation of IKK in a fashion similar to that of
TNF- alone, although phosphorylation was nonsignifi-
cantly increased in all instances (Figure 2B).
TGF-1 induced significant phosphorylation of TAK1
from 1 minute onward, peaking at 10 minutes and remain-
ing phosphorylated for at least 60 minutes. TNF- alone
induced significant phosphorylation of TAK1 from 10 min-
utes onward, peaking at 30 minutes and again lasting
beyond 60 minutes, although the level of phosphorylation
was lower compared to TGF-1 stimulations. Co-stimula-
tion induced significant phosphorylation of TAK1 from 1
minute onward, peaking at approximately 10 minutes,
and again lasting beyond 60 minutes with an accentu-
ated, as opposed to additive, effect observed from 5
minutes onward (Figure 2C). TGF-1 stimulation also in-
duced a significant increase in JNK-1/2 phosphorylation
at 5 and 10 minutes, with significance lost beyond 30
minutes. TNF- alone induced significant phosphoryla-
tion of JNK-1/2 from 5 minutes onward, peaking at 10
minutes with significance lost beyond 30 minutes. The
degree of phosphorylation with TNF- treatment was
greater than that seen with TGF-1. Co-stimulation in-
duced significant phosphorylation of JNK-1/2 from 1 min-
ute onward, peaking at 10 minutes and lasting beyond 60
minutes with an accentuated effect observed at 1, 30,
and 60 minute in co-stimulated cells compared to those
stimulated with TGF-1 or TNF- alone (Figure 2D).
In all instances, selected samples were analyzed by
Western blot, alongside IgG controls to demonstrate ef-
ficacy and specificity of pull down (Figure 2E). Total ly-
sate from PBECs stimulated with TGF-1 or TNF- for 30
minutes were analyzed by Western blot for total and
phosphorylated forms of key signaling proteins. For sig-
naling molecules already discussed, the effect was sim-
ilar to that observed by indirect ELISA. In addition, neither
p38 nor ERK-1/2 displayed any change in phosphoryla-
tion (Figure 2F).
Unpicking the Signaling Cascade
We proceeded to investigate the effects of inhibiting
SMAD3, IKK, TAK1, and JNK-1/2 on TGF-1–driven EMT,
and its accentuation by TNF- alongside the concomitant
effect on phosphorylation of other key signaling molecules.
Pretreatment with SMADi strongly reduced SMAD3
phosphorylation 30 minutes poststimulation with TGF-1
or TNF-, with no detected change in the phosphorylation
of other signaling molecules (Figure 3A; see also Supple-
mental Figure S1A at http://ajp.amjpathol.org). Pretreat-
ment of PBECs with SMADi prevented the change in cell
morphology, the down-regulation of E-cadherin expres-
sion, the increase in fibronectin and vimentin expression,
and the increase in pro-MMP-9 and collagen I-IV secretion
in response to TGF-1, returning levels to near baseline.
sol
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markers compared to untreated control PBECs, however,
an accentuated effect was still apparent for all markers with
Figure 1. TNF- accentuates TGF-1–driven EMT via TNFR1. A: Flow cyt
express little to no TNFR2. B: Stimulation of PBECs (n 6) with soluble TNF-
86T) membrane-bound TNF (TNFcysR1), or TNFR2-specific mutant (Cys-TNF
no effect on the expression of E-cadherin, vimentin, or fibronectin. Stimulatio
secretion. TGF-1 (10 ng/mL) down-regulates the expression of E-cadherin,
pro-MMP-9. Co-stimulation of the cells with TGF-1 and TNFsol, TNFcys, o
compared to TGF-1 alone. C: Co-stimulation of PBECs with TGF-1 and TN
and EMT marker expression compared to TGF-1 alone. FL1-H, height of flthe exception of collagens I-IV when comparing co-stim-ulated PBECs with TGF-1 alone stimulated PBECs in the
presence of SMADi (Figure 3, B and D; see also Supple-
mental Figure S2A at http://ajp.amjpathol.org). Approxi-
analysis demonstrates that PBECs express TNFR1 on their cell surface, but
ol), membrane-bound TNF- (TNFcys), TNFR1-specific mutant (Cys-TNF32W/
5R) membrane-bound TNF (TNFcysR2) (all 20 ng/mL) for 72 hours alone has
ver, with TNFsol, TNFcys, or TNFcysR1, but not TNFcysR2, increases pro-MMP-9
s the expression of vimentin and fibronectin, and increases the secretion of
R1, but not TNFcysR2, accentuates the changes in EMT marker expression
Fcys, or TNFcysR1, but not TNFcysR2, accentuates changes in cell morphology
ce intensity; FSC-H, height of forward scatter; SSC-H, height of side scatter.ometry
 (TNFs
143N/14
n, howe
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r TNFcys
F , TNmately 90% knockdown of SMAD3 was achieved by
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AJP June 2012, Vol. 180, No. 6Figure 2. TAK1 and JNK-2 display accentuated and prolonged phosphorylation in response to TGF-1 and TNF- stimulation. Indirect ELISA for the
phosphorylation of SMAD3, IKK, TAK1, and JNK-1/2 were performed on PBEC lysates immunoprecipitated for SMAD3, IKK, TAK1, and JNK-1/2, respectively.
*P  0.05 (n  3). A: Stimulation with TGF-1 (10 ng/mL) induces significant SMAD3 phosphorylation (Ser423  Ser425) from 30 minutes onwards. Stimulation
with TNF- (20 ng/mL) does not significantly increase SMAD3 phosphorylation. Co-stimulation with TGF-1 and TNF- do not increase the phosphorylation of
SMAD3 compared to TGF-1 alone. B: TGF-1 does not induce significant IKK phosphorylation (Tyr199) at any time point. Stimulation with TNF- induces
significant phosphorylation of IKK from 1 minute and lasting up to 30 minutes. Co-stimulation with TGF-1 and TNF- does not accentuate the phosphorylation
of IKK compared to TNF- alone, although an additive increase in IKK phosphorylation is observed. C: TGF-1 induces significant TAK1 phosphorylation
(Thr187) from 1 minute, peaking at 10 minutes, and lasting to at least 60 minutes. Stimulation with TNF- induces significant phosphorylation of TAK1 from 10
minutes, peaking at 30 minutes, and lasting beyond 60 minutes, although the amount of phosphorylation was lower than that seen with TGF-1 alone.
Co-stimulation with TGF-1 and TNF- induces significant phosphorylation of TAK1 from 1 minute, peaking at 10 minutes, and again lasting beyond 60 minutes.
A significant accenting effect is observed from 5 minutes onward compared to cells treated with TGF-1 or TNF- alone. D: TGF-1 induces significant JNK-1/2
phosphorylation (Thr183  Tyr185) at 5 and 10 minutes. Stimulation with TNF- induces significant phosphorylation of JNK-1/2 from 5 minutes and lasting up
to 30 minutes. The degree of phosphorylation induced by treatment with TNF- is greater than that with TGF-1. Co-stimulation with TGF-1 and TNF- induces
significant phosphorylation of JNK-1/2 from 1 minute, peaking at 10 minutes and lasting beyond 60 minutes. A significant accenting effect is observed at 1, 30,
and 60 minutes in co-treated cells compared to cells treated with TGF-1 or TNF- alone. E: Selected immunoprecipitates and matching IgG controls were
analyzed by Western blot to demonstrate the efficacy and specificity of the immunoprecipitates. Significant specificity for all of the antibodies used compared to
IgG controls is observed. F: Total lysate from PBECs stimulated with TGF-1 or TNF- for 30 minutes were analyzed by Western blot for total and phosphorylated
forms of key signaling proteins. Phosphorylation of SMAD3, IKK, TAK1, and JNK-1/2 is similar to that observed by indirect ELISA. In addition, neither p38 nor
ERK-1/2 displays any change in phosphorylation in response to treatment.
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AJP June 2012, Vol. 180, No. 6Figure 3. Blocking SMAD3 activity limits TGF-1–driven EMT. A: Stimulation of PBECs (n  3) with TGF-1 (10 ng/mL) or TNF- (20 ng/mL) induces
phosphorylation of p38, SMAD3, IKK, TAK1, and JNK-1/2, as described in Figure 2. Pretreatment with specific inhibitor of SMAD3 (SMADi) (10 mol/L) strongly
attenuates the phosphorylation of SMAD3, but has no effect on the phosphorylation of p38, IKK, TAK1, and JNK-1/2. B: Stimulation of PBECs (n  4) with
TGF-1 down-regulates E-cadherin expression, increases fibronectin and vimentin expression, and increases pro-matrix metalloproteinases (MMP)-9 secretion.
This change in EMT marker expression is accentuated by co-stimulation with TGF-1 and TNF-. Collagen I-IV secretion is significantly up-regulated by
stimulation with TGF-1, however, no accentuation is observed on co-stimulation. Pretreatment with SMADi attenuates both TGF-1–driven and TNF-–
accentuated changes in EMT marker expression and collagen I-IV secretion, returning levels to near baseline. C: Treatment of PBECs (n  3) with SMADsi (5
nmol/L) induces an approximate 90% knockdown of total SMAD3 after 24 hours, with no phosphorylation of SMAD3 detected after stimulation with TGF-1 or
TNF- for 30 minutes. Knockdown of SMAD3 inhibits both the TGF-1–driven and TNF-–accentuated down-regulation of E-cadherin expression, the increase
in fibronectin and vimentin expression, and the increase in collagen I-IV and pro-MMP-9 secretion compared to uninhibited controls. A sequence scrambled
control has no effect on EMT marker expression. *P  0.05. D: A549 cells treated with TGF-1 begin to lose their epithelial morphology and acquire a more
elongated mesenchymal morphology, and this change is accentuated by co-stimulation with TNF-. Pretreatment with SMADi attenuates this morphological
change in both TGF-1 and co-treated cells.
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of detected phospho-SMAD3 30 minutes after stimulation
with TGF-1 or TNF-. SMADsi inhibited TGF-1–driven
and TNF-–accentuated EMT in a similar fashion to
SMADi (Figure 3C; see also Supplemental Figure S2B at
http://ajp.amjpathol.org).
Pretreatment with IKKi did not block the phosphoryla-
tion of any of the key signaling proteins investigated,
however, phosphorylation of I-B, the main substrate of
IKK within the NF-B cascade, was strongly reduced
(Figure 4A; see also Supplemental Figure S1B at http://
ajp.amjpathol.org). Pretreatment with IKKi inhibited the
TGF-1 induced down-regulation of E-cadherin expres-
sion, the increase in fibronectin and vimentin expression,
and, slightly, the increase in collagen I-IV and pro-MMP-9
secretion. IKKi strongly reduced the accentuating effect
of TNF- on TGF-1–driven EMT marker expression, re-
storing protein levels to those of TGF-1 stimulated
PBECs (Figure 4B; see also Supplemental Figure S2C at
http://ajp.amjpathol.org). IKKi also slightly inhibited the
TGF-1 induced change in cell morphology, but strongly
limited the accentuation of this effect by TNF- (Figure
4D). IKKsi induced approximately a 90% reduction in
detected IKK and also strongly reduced the detected
levels of phospho-IKK. IKKsi inhibited the TGF-1 me-
diated loss of E-cadherin, but displayed only weak inhib-
itory effects on other EMT markers. However IKKsi
strongly inhibited the TNF- mediated accentuation of
TGF-1–driven EMT for all markers with the exception of
collagens I-IV (Figure 4C; see also Supplemental Figure
S2D at http://ajp.amjpathol.org).
No difference in the phosphorylation of SMAD3 or p38
following stimulation with TGF-1 or TNF- in the pres-
ence of TAKi was demonstrated, however, TAK1 phos-
phorylation was completely inhibited and the phosphor-
ylation of IKK and JNK-2 was reduced (Figure 5A; see
also Supplemental Figure S3A at http://ajp.amjpathol.org).
Pretreatment of PBECs with TAKi prevented the change
in cell morphology, the down-regulation of E-cadherin
expression, and the increase in fibronectin and vimentin
expression in response to TGF-1, returning levels to
near baseline. In addition the increased collagen I-IV
secretion seen in PBECs treated with TGF-1 was re-
turned to near baseline in the presence of TAKi, which
also reduced the accentuating effect of TNF- on TGF-
1–driven EMT for the aforementioned EMT markers.
TAKi decreased pro-MMP-9 secretion from TGF-1
treated cells, however, in cells treated with TNF- alone,
or TGF-1 and TNF- TAKi increased the secretion of
pro-MMP-9 (Figure 5, B and D; see also Supplemental
Figure S4A at http://ajp.amjpathol.org). TAKsi induced a
strong reduction in detected levels of total TAK1, along
with a strong reduction in detected levels of phospho-
TAK1 after 24 hours. TAKsi inhibited the TGF-1 induced
decrease in E-cadherin expression, increase in fibronec-
tin and vimentin expression, and significantly inhibited
the increase in secretion of collagens I-IV seen in control
cells or cells treated with the scrambled siRNA, returning
expression levels for all proteins to near baseline. TAK1
knockdown also reduced the accentuating effect of
TNF- on TGF-1–driven EMT in PBECs. In contrast tothe described results for TAKi in which pro-MMP-9 secre-
tion was enhanced by TAKi (Figure 5B), pro-MMP-9 se-
cretion after TAKsi treatment displayed a return to near
baseline across all stimulations (Figure 5C; see also Sup-
plemental Figure S4B at http://ajp.amjpathol.org).
JNKi inhibited the phosphorylation of JNK-1/2 and c-
Jun, with no effect observed on any of the other signaling
proteins assayed (Figure 6A; see also Supplemental Fig-
ure S3B at http://ajp.amjpathol.org). Pretreatment of
PBECs with JNKi had a similar inhibitory effect to that of
TAKi on TGF-1–driven EMT and TNF-–accentuated
TGF-1–driven EMT (Figure 6, B and D; see also Sup-
plemental Figure S4C at http://ajp.amjpathol.org). Knock-
down of JNK-2 inhibited the TGF-1–induced decrease
in E-cadherin expression, increase in fibronectin and
vimentin expression, and significantly inhibited the in-
crease in secretion of collagens I-IV seen in control
cells returning expression levels for all proteins to near
baseline. JNK-2 knockdown also reduced the accen-
tuating effect of TNF- on TGF-1–driven EMT in
PBECs. In contrast, knockdown of JNK-1 did not inhibit
the TGF-1–driven or TNF-–accentuated decrease in
E-cadherin expression or increase in fibronectin and
vimentin expression, but did reduce pro-MMP-9 and
collagens I-IV secretion compared to untreated con-
trols (Figure 6C; see also Supplemental Figure S4D at
http://ajp.amjpathol.org).
Disease Relevance of TAK1
Sequential sections from OB lung tissue and unused
donor lung as a control were used to investigate the
localization and phosphorylation of TAK1 in the airway.
Sections were stained for either total TAK1 or phospho-
TAK1 and counterstained with the epithelial marker
E-cadherin and DAPI as a nuclear marker. Total TAK1
was located throughout all airway cells and there was
no detectable difference in the intensity of expression
between normal and OB lung tissue. In contrast levels
of phospho-TAK1 were higher in epithelial cells in OB
tissue compared to normal. It was also noted that phos-
pho-TAK1 displayed evidence of nuclear localization,
which was more pronounced in OB tissue (Figure 7A;
see also Supplemental Figure S5A at http://ajp.
amjpathol.org).
To quantify the observations previously described, im-
munocytochemistry was performed on cultured PBECs
treated with TGF-1 or TNF- for 30 minutes, and the
relative nuclear localization of phospho-TAK1 assessed.
PBECs were stained with phospho-TAK1 and -actin,
along with DAPI as a nuclear counterstain. Nuclear local-
ization of phospho-TAK1 was increased following stimu-
lation with both TGF-1 (74.5  1.7) and, to a lesser
extent, TNF- (29.8  1.0) compared to control cells
(5.1  0.1). Co-stimulation with TGF-1 and TNF- re-
sulted in an accentuated nuclear localization of phospho-
TAK1 (156.2  5.6) compared to either TGF-1 or TNF-
stimulation alone (Figure 7, B and C; see also Supple-
mental Figure S5B at http://ajp.amjpathol.org). Alongside
this, to confirm the observed nuclear translocation of
TAK1, nuclear and non-nuclear fractions were prepared
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AJP June 2012, Vol. 180, No. 6Figure 4. IKK blocking IKK activity limits TGF-1–driven EMT and its accentuation. A: Stimulation of PBECs (n  3) with TGF-1 (10 ng/mL) or TNF-
(20 ng/mL) induce phosphorylation of p38, SMAD3, IKK, TAK1, and JNK-1/2 as described in Figure 2. Pretreatment with IKK-2 Inhibitor IV (IKKi) (5
mol/L) for 1 hour strongly reduces the phosphorylation of I-B, but has no effect on the phosphorylation of p38, SMAD3, IKK, TAK1, and JNK-1/2.
B: Stimulation of PBECs (n  4) with TGF-1 down-regulates E-cadherin expression, increases fibronectin and vimentin expression, and increases
pro-MMP-9 secretion. This change in EMT marker expression is accentuated by co-stimulation with TGF-1 and TNF-. Collagen I-IV secretion is
up-regulated by stimulation with TGF-1, however, no accentuation is observed on co-stimulation with TGF-1 and TNF-. Pretreatment with IKKi
attenuates both TGF-1–driven and TNF-–accentuated changes in EMT marker expression and collagen I-IV secretion, returning levels to near baseline.
C: Treatment of PBECs with IKKsi (0.1 nmol/L) induces an approximate 90% knockdown of total IKK after 24 hours and strongly reduces detected IKK
phosphorylation after stimulation with TGF-1 or TNF- for 30 minutes. Knockdown of IKK has a small inhibitory effect on TGF-1–driven EMT, but
strongly attenuates the TNF-–accentuated change in EMT marker expression. In contrast, TGF-1 induced collagen I-IV secretion is not inhibited by
knockdown of IKK. A sequence scrambled control has no effect on EMT marker expression. *P  0.05. D: A549 cells treated with TGF-1 begin to lose
their epithelial morphology and acquire a more elongated mesenchymal morphology, and this change is accentuated by co-stimulation with TNF-.
Pretreatment with IKKi has little to no effect on the TGF-1 induced change in cell morphology, but strongly attenuates the accentuating effect of TNF-
on cell morphology.
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AJP June 2012, Vol. 180, No. 6Figure 5. Blocking TGF-1–activated TAK1 activity limits TGF-1–driven EMT and its accentuation by TNF-. A: Stimulation of PBECs (n  3) with TGF-1 (10
ng/mL) or TNF- (20 ng/mL) induces phosphorylation of p38, SMAD3, IKK, TAK1, and JNK-1/2, as described in Figure 2. Pretreatment with (5Z)–7-Oxozeaenol,
Curvularia spp. (TAKi) (1 mol/L) for 1 hour strongly reduces the phosphorylation of TAK1, IKK, and JNK-1/2, but has no effect on p38 or SMAD3
phosphorylation. B: Stimulation of PBECs (n  6) with TGF-1 down-regulates E-cadherin expression, increases fibronectin and vimentin expression, and
increases pro-MMP-9 secretion. This change in EMT marker expression is accentuated by co-stimulation with TNF-. Collagen I-IV secretion is significantly
up-regulated by stimulation with TGF-1, however, no accentuation is observed on co-stimulation with TNF-. Pretreatment with TAKi attenuates the
TGF-1–driven changes in EMT marker expression and collagen secretion and the TNF-–accentuated change in E-cadherin, fibronectin and vimentin expression,
and collagen I-IV secretion compared to untreated cells. Conversely, TAKi increases secretion of pro-MMP-9 in PBECs treated with TNF- alone or in combination
with TGF-1. C: Treatment of PBECs (n  5) with TAKsi (5 nmol/L) induces an approximate 80% knockdown of total TAK1 after 24 hours and strongly reduces
detected phosphorylation after stimulation with TGF-1 or TNF- for 30 minutes. Knockdown of TAK1 also strongly reduces both TGF-1–driven and
TNF-–accentuated changes in EMT marker expression and secretion of collagen I-IV and pro-MMP-9 compared to uninhibited controls. A sequence scrambled
control has no effect on EMT marker expression. *P  0.05. D: A549 cells treated with TGF-1 begin to lose their epithelial morphology and acquire a more
elongated mesenchymal morphology, and this change is accentuated by co-stimulation with TNF-. Pretreatment with TAKi attenuates this morphological change
in cells treated with TGF-1 alone or in combination with TNF-.
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AJP June 2012, Vol. 180, No. 6Figure 6. Blocking JNK-1/2 activity limits TGF-1–driven EMT and its accentuation by TNF-. A: Stimulation of primary bronchial epithelial cells (PBECs) (n 3) with
TGF-1 (10 ng/mL) or TNF- (20 ng/mL) induces phosphorylation of p38, SMAD3, IKK, TAK1, and JNK-1/2, as described in Figure 2. Pretreatment with SAPK Inhibitor
II (JNKi) (5 mol/L) for 1 hour strongly reduces the phosphorylation of JNK-1/2 and c-Jun, but has no effect on p38, SMAD3, IKK, and TAK1 phosphorylation. Total
c-Jun is increased in PBECs stimulated with TGF-1 or TNF- alone, or in combination, and this was not affected by pretreatment with JNKi. B: Stimulation of PBECs
(n  4) with TGF-1 down-regulates E-cadherin expression, increases fibronectin and vimentin expression, and increases pro-MMP-9 secretion. This change in EMT
marker expression is accentuated by co-stimulation with TNF-. Collagen I-IV secretion is significantly up-regulated by stimulation with TGF-1, however, no
accentuation is observed on co-stimulation with TNF-. Pretreatment with JNKi attenuates both TGF-1–driven and TNF-–accentuated changes in EMT marker
expression and collagen I-IV secretion, returning levels to near baseline. C: Treatment of PBECs (n  3) with JNK-1si (10 nmol/L) and JNK-2si (10 nmol/L) induces an
approximate 95% knockdown of total JNK-1 or JNK-2, respectively, after 24 hours, and strongly and selectively reduces their phosphorylation after stimulation with
TGF-1 or TNF- for 30 minutes. JNK-2si also strongly reduced TGF-1–driven and TNF-–accentuated changes in EMT marker expression and collagen I-IV, and
pro-MMP-9 secretion, returning levels to near baseline. In contrast JNK-1si has no effect on the down-regulation of E-cadherin expression or the increase in fibronectin
and vimentin expression. JNK-1si, however, attenuates the increase in pro-MMP-9 and collagen I-IV secretion compared to untreated cells. A sequence scrambled control
has no effect on EMT marker expression. *P  0.05. D: A549 cells treated with TGF-1 begin to lose their epithelial morphology and acquire a more elongated
mesenchymal morphology, and this change is accentuated by co-stimulation with TNF-. Pretreatment with JNKi has little to no effect on the TGF-1–induced change
in cell morphology, but strongly attenuates the accentuating effect of TNF- on cell morphology.
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AJP June 2012, Vol. 180, No. 6Figure 7. TAK1 nuclear localization in OB tissue and PBECs. A: Tissue sections from normal and OB lungs were stained for either total TAK1 or phospho-TAK1,
and expression and localization assessed in the epithelium. E-cadherin was used as an epithelial marker. Total TAK1 staining is located throughout the cell with
no difference in expression levels between normal and OB tissue. In contrast phospho-TAK1 staining is more intense and shows an increased nuclear localization
in OB tissue compared to the normal lung. The phospho-TAK1 antibody displays nonspecific binding of the antibody to the brush border of the airway in both
control and OB sections. B: Untreated PBECs express little to no phospho-TAK1. Stimulation with either TGF-1 or TNF- induces an increased phosphorylation
of TAK1 and a pronounced localization of TAK1 to the nucleus. Co-stimulation with TGF-1 and TNF- accentuates both the phosphorylation of TAK1, as well
as the nuclear localization of the phosphorylated protein. C: Mean pixel intensity of phospho-TAK1 staining in the nuclei in response to stimulation in 20 cells
quantified from multiple images. Results are expressed as mean SEM. D: The presence and degree of phosphorylation of TAK1 in both nuclear and non-nuclear
fractions isolated from PBECs treated, as indicated was assessed. RAN (a nuclear specific RAS-GTPase) and E-cadherin (a cell membrane marker) ere used to
demonstrate purity of nuclear and non-nuclear fractions, respectively. Total TAK1 levels are detected in both nuclear and non-nuclear fractions and remain
unchanged in response to stimulation. Phospho-TAK1 is increased in both the nuclear and non-nuclear fractions in response to treatment with TGF-1 and TNF-
with an accentuation seen on co-stimulation.
iation w
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The cell adhesion protein E-cadherin and rat sarcoma-
related nuclear protein (Ran), a nuclear specific rat sar-
coma guanosine triphosphate hydrolase enzyme, were
used as markers to confirm the purity of the respective
fractions. Phospho-TAK1 is expressed in both the nuclear
and non-nuclear fractions and displays the same accen-
tuated response to stimulation with TGF-1 and TNF-
described in both total cell lysate Western blots and
immunocytochemistry (Figure 7D).
Potential Role for c-Jun
PBEC lysates from cells stimulated with TGF-1 or TNF-
for 30 minutes were immunoprecipitated under nondena-
turing conditions with TAK1 and SMAD3 antibodies and
probed for a variety of markers. The TAK1 associated
binding protein (TAB) family facilitate TAK1 autophos-
phorylation27 through interaction with receptor scaffold
proteins, such as TNF receptor-associated factor 6. TAB1
was associated with TAK1 under all conditions, however,
TAB2 and TAB3 associated with TAK1 on stimulation with
TGF-1, but not TNF-. On co-stimulation, there was no
change in TAB3 association compared to TGF-1 alone,
but TAB2 association with TAK1 was completely lost.
IKK and JNK-2, but not JNK-1 or SMAD3, were associ-
ated with TAK1 at 30 minutes after stimulation with
TGF-1 or TNF-, with no differences in association be-
tween stimulations. In contrast, c-Jun was associated
Figure 8. c-Jun as the effector of accentuated and prolonged TAK1, JNK-2 p
or TNF- (20 ng/mL) for 30 minutes were immunoprecipitated for total TAK1
TAB1 is associated with TAK1 on treatment with TGF-1 or TNF-, with an
TAK1 on treatment with TGF-1, but not TNF-. On co-treatment TAB3 rema
with TAK1 after treatment with TGF-1 or TNF- alone, or in combination,
c-Jun is associated with TAK1 only after co-stimulation with both TGF-1 a
treatment conditions. B: PBEC lysates (n  2) treated as previously describ
phosphorylated forms of TAK1 and c-June. Total c-Jun has a weak assoc
combination. No association between total or phosphorylated TAK-1 or phowith TAK1 only after co-stimulation with both TGF-1 andTNF- (Figure 8A). c-Jun was detected in association
with SMAD3 under all stimulations, however, the phospho
form and the total and phospho forms of TAK1 were not
associated with SMAD3 in response to any treatment
(Figure 8B).
Discussion
Current therapies to limit or reverse fibrosis have failed to
demonstrate significant clinical benefits highlighting the
need for further research to elucidate the basic mecha-
nisms underlying disease progression, particularly the
link between fibrosis and inflammation. Recently, our
group and others have shown that TGF-1 can drive EMT
in PBECs, and inflammatory stimuli, such as TNF- and
IL-1 can accentuate this effect,2,14,15 however, the sig-
naling mechanisms are ill-defined. In this article, we pro-
vide novel insight into the signaling events involved in the
accentuation of TGF-1–driven EMT elicited by TNF-. It
is our hope that greater understanding of the interaction
between pro-fibrotic and pro-inflammatory mediators will
help with the development of new more targeted thera-
peutics along with the development of potential prognos-
tic biomarkers.
Our data suggest that SMAD3 mediated TGF-1–
driven EMT is indirectly controlled by TAK1/JNK-2 acti-
vation possibly through association c-Jun. TNF- accen-
tuates EMT through IKK directly controlled by TAK1,
and indirectly by JNK-2, again possibly by the actions of
rylation. A: PBEC lysates (n  3) from cells treated with TGF-1 (10 ng/mL)
IgG and probed for total TAK1, SMAD3, IKK, JNK-1/2, c-Jun, and TAB 1–3.
ated association on co-treatment. Both TAB2 and TAB3 are associated with
iated with TAK1, but TAB2 is completely lost. IKK and JNK-2 are associated
no difference in the degree of association between treatments is observed.
-. In contrast, SMAD3 and JNK-1 are not associated with TAK1 under any
immunoprecipitated for total SMAD3, or pan-IgG and probed for total and
ith SMAD3 in response to treatment with TGF-1 and TNF- alone or in
lated c-Jun was observed.hospho
or pan-
accentu
ins assoc
although
nd TNF
ed werec-Jun. Co-stimulation resulted in accentuated phosphor-
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TAK1JNK2-c-Jun cascade plays an important role in
the accentuated EMT observed in co-stimulated PBECs.
TAK1 was initially described as a mediator of nonca-
nonical TGF- signaling,28 although it is now also known
to play a key role in NF-B signaling. Both TGF-1 and
TNF- alone promote the phosphorylation, and hence
activation,29 of TAK1, and we demonstrate that this phos-
phorylation is accentuated and prolonged on co-stimula-
tion, with an associated nuclear translocation. TAK1 does
not contain a described nuclear translocation signal and
no evidence of direct transcriptional control has been
presented in the literature, therefore, the observed local-
ization of TAK1 to the nucleus in response to stimulation
was unexpected. We identified two previous studies,
however, describing a nuclear localization of TAK1; the
first describes localization in response to IL-6 stimulation
and the second describes the translocation of TAK1 into
the nucleus in association with Ski-related novel protein N
(SnoN), an inhibitor of SMAD transcriptional activity. In
this instance, TAK1 is required for the degradation of
SnoN and the consequent activation of SMAD transcrip-
tional activity.30 In our system, it is possible that our
accentuated activation of TAK1 may result in an even
greater inhibition of SnoN activity and an increase in
resultant SMAD transcriptional activity, although further
investigation is required to test this hypothesis.
The TAB family consists of three members, which are
thought to modulate TAK1 function. The most widely in-
vestigated member is TAB1, a pseudo-phosphatase that
is responsible for the induction of TAK1 activity via pro-
motion of autophosphorylation of residues within the ac-
tivation loop. It is thought that TAB1 and TAK1 are con-
stitutively associated and that TAB1 is required for TAK1
autophosphorylation,27 in line with our findings. TAB2
and TAB3 are involved in the recruitment and binding of
other proteins to TAK1 to form complexes that can mod-
ulate TAK1 activity, and may help explain the observed
nuclear translocation and described phosphorylation re-
sponse. The data presented in this article suggests that
the interactions of TAB2 and TAB3 with TAK1 may be of
interest in understanding the mechanisms underlying the
accentuated phosphorylation of TAK1 and resultant EMT.
JNK-2 binds c-Jun with a higher affinity than JNK-131,
however, a previous study investigating EMT in primary
murine tracheal cells demonstrated an important role for
JNK-1, independent of JNK-2, in mediating SMAD3 de-
pendant, TGF-1–driven EMT.32 The dose of JNKi used
in this study does not differentiate between JNK isoforms,
and therefore the observed inhibitory effect on EMT could
occur due to the inhibition of JNK-1, JNK-2, or both in
these experiments. However, our data also demonstrated
an increase in JNK-2, but not JNK-1 phosphorylation in
response to treatments, and while JNK-2si strongly inhib-
ited EMT for all markers, JNK-1si only reduced the secre-
tion of pro-MMP-9 and collagens I-IV. Together the data
suggest that JNK-1 and JNK-2 may act cooperatively;
indeed JNK-1 has been shown to phosphorylate JNK-2
before both phosphorylate p53 at separate activating
residues33, however, we did not observe any change inJNK-1 phosphorylation suggesting that its presence
rather than activation may be of importance.
JNK-2 also displayed an accentuated and prolonged
phosphorylation on co-stimulation, and its inhibition, un-
like other members of the mitogen-activated protein ki-
nase pathway (p38 and ERK1/2), blocked EMT. The lack
of response from ERK-1/2 and p38 (see Supplemental
Figure S6 at http://ajp.amjpathol.org) was surprising, as
both have been demonstrated to respond to similar stim-
uli in other models34,35 and a role for TAK1 mediated
activation of ERK-1/2 and p38 has also been de-
scribed.36 However, our results are in agreement with
previous reports demonstrating that inhibition of p38 or
ERK-1 have no effect on TGF-1–driven or TGF-1–
driven, TNF-–accentuated EMT15,37, suggesting that
signaling pathways controlling EMT may be cell or tissue
dependent. Further evidence of this varied response in
different tissues is demonstrated in two articles specifi-
cally investigating the role of TAK1 in fibrosis; the first38
describes TAK1 as a key mediator of fibrosis and inflam-
mation within the kidney via the activation of p38, JNK,
and NF-B. Whereas the other article demonstrates an
opposite effect, with ablation of TAK1 increasing the de-
velopment of inflammation and fibrosis in hepatic cells.39
Throughout the study, we did not observe an additive
or accentuated increase in collagen secretion in re-
sponse to TNF- stimulation. Previous studies have dem-
onstrated that TNF- can inhibit collagen production.40
Taken together with our data on the expression of other
markers of EMT, it may be that co-stimulation with TGF-1
and TNF- results in a higher proportion of mesenchy-
mal-like cells that produce less collagen on a per cell
basis than cells stimulated with TGF-1 alone. This raises
the intriguing possibility that episodic release of TNF- in
the presence of TGF-1, such as could occur in response
to repeated inflammatory insults to the lung, could drive
migration and invasion of transformed epithelial cells, but
not deposition of collagen until the levels of TNF- fall
again, in which case the transformed cells could then
drive fibrosis.
Here, we have identified a role for a TAK1 in orches-
trating synergy between TGF-1 and TNF- in driving
EMT in the development of OB. EMT, however, has also
been identified as a potential mechanism contributing to
the development of other fibrotic disorders of the lung
characterized by elevated TGF-1, such as idiopathic
pulmonary fibrosis9 and asthma.41 Furthermore, in the
kidney TGF-1–driven EMT has been suggested to play
an important role in the development of fibrosis,42
whereas a role for inflammatory mediators secreted from
leukocytes has also been described.43 Similarly, a poten-
tial role for TGF-1–driven EMT has been described dur-
ing the development of liver fibrosis.44 Considering the
ubiquitous expression of TAK1 and the potential role of
EMT in tissue fibrosis, we propose that the signaling
pathway identified in this article may be important in
several fibrotic diseases across multiple organs. Indeed,
several mitogen-activated protein kinase inhibitors de-
signed to limit fibrosis in idiopathic pulmonary fibrosis are
currently undergoing clinical trials, such as inhibitors
of p38 (NCT01203943) and JNK (NCT01366209) and
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There are currently no clinical trials using inhibitors
against TAK-1, and it is unlikely that direct inhibition of
TAK-1 itself will be an acceptable therapeutic target,
reinforced by the embryo lethal nature of TAK1 knockout
mice.45 Further investigations, therefore, are underway to
identify the upstream modulators and downstream effec-
tors of TAK1 and JNK-2 activation that may identify alter-
native, more suitable therapeutic targets.
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